Background and Aims. Although epidural analgesia is still regarded as the gold standard for labour analgesia due to its efficacy, in cases of contraindication, systemic remifentanil is an alternative. Since the first demonstration of the safety of remifentanil in obstetric analgesia in 1996, this has been repeatedly confirmed for both mother and newborn. The aim of this meta-analysis is to evaluate recently published studies (up to December 2014) on the analgesic efficacy of remifentanil during labour (as a Visual Analogue Scale (VAS) decrease in the first hour by 2 or more). Methods. Search of the US National Library of Medicine, National Institutes of Health (www.pubmed.gov), SCOPUS database (www.scopus.com) and Web of Science database (www.webofknowledge.com) using the key words "labour" and "remifentanil". 44 identified articles were included in the review and 15 published randomised controlled studies were incorporated into the meta-analysis. This was based on the fixed model and described by differences in the VAS between t=0 and t=1 hour after remifentanil administration using the 95% confidence interval (CI). The analysis was computed using the Comprehensive meta-analysis version 2.2.064. Results. The combined data from the meta-analysis showed a statistically significant decrease in VAS in the remifentanil group. From a comparison of the CIs of summary estimates with a cut-off decrease of VAS 2, for the fixed model, there was a statistically significantly greater decrease in VAS than the cut-off. In the systematic review, we describe possible modes of application, dosage and side-effects for mother, fetus/ newborn. Conclusion. The meta-analysis presented here confirms that remifentanil for labour analgesia is effective but questions remain which can only be answered by further randomized trials.
INTRODUCTION
Most frequent contraindications to epidural analgesia, long considered the "gold" standard for labour analgesia, are refusal of parturient, congenital or acquired coagulopathy and infection 1 . The most commonly used opioid in the past was pethidine, despite the well-described side effects of its metabolite, norpethidine, for both mother and newborn [2] [3] [4] [5] [6] [7] . Another currently used opioid is nalbuphine but this only reduces the pain slightly [8] [9] [10] [11] . Remifentanil is a synthetic 4-anilide-piperidine, sidechain linked by an ester bond, which is responsible for its rapid inactivation by non-specific hydrolysis of plasma and tissue esterases 12 . The onset time is reported on average to be 1.3 min and the context-sensitive half-time 3 min, regardless of the duration of the infusion 13 . Remifentanil is a selective μ-opioid agonist and has the same adverse effects as other opioids. The first demonstration of its use in obstetric analgesia was in 1996 and since then its safety for both mother and newborn has been repeatedly confirmed [14] [15] [16] [17] .
In European countries, such as Great Britain, Belgium, France and the Scandinavian countries, the administration of remifenatnil for labour is relatively common but not nearly routine 2, [18] [19] [20] . The reason for this may be both lack of experience of individual departments with this form of analgesia and the fact that it can be applied almost exclusively with a patient-controlled analgesia pump (PCA) (ref. 21 ). Remifentanil in PCA mode is relatively well-tolerated and this increases the satisfaction of the parturient with pain management 15, [22] [23] [24] . The aim of this meta-analysis was to evaluate the literature on the analgesic efficacy of remifentanil during labour (measured as a Visual Analogue Scale (VAS) decrease in the first hour by 2 or more). We describe possible modes of application, dosage and side-effects for mother, fetus/ newborn.
Search of the US National Library of Medicine, National Institutes of Health (www.pubmed.gov) using the key words "labour" and "remifentanil" provided us with 159 links to publications where more than half (82) were published in the last 5 years and only 30 publications were older than 10 years. This confirms that remifentanil is an extremely hot topic in labour anaesthesia.
METHODS
This article followed PRISMA Statement (www.prisma-statement.org) for meta-analysis and reviews.
Searching strategy for review
Search of the US National Library of Medicine, National Institutes of Health (www.pubmed.gov), SCOPUS database (www.scopus.com) and Web of Science database (www.webofknowledge.com) using the key words "labour" and "remifentanil". The last search was performed on December 1, 2014.
Inclusion criteria for meta-analysis
Randomized Controlled Trials (RCTs) meeting the following criteria were included: measured Visual Analogue Scale at time 0 min (t=0) and at 60 min (t=1) after initiation of analgesia; full-text articles available; and presence of detailed clinical data.
Exclusion criteria for meta-analysis
Not randomized controlled study. Missing full article text and missing detailed clinical data or Visual Analogue Scale at times 0 and 60 min.
Statistical analysis
Standard descriptive statistics were applied for VAS, means and standard deviations. The meta-analysis was based on fixed model and described by the difference in the VAS between t=0 and t=1 in the remifentanil group and the corresponding 95% confidence interval. The analysis was computed using the Comprehensive metaanalysis version 2.2.064.
RESULTS

Flowchart
The PRISMA flowchart is shown in Fig. 1 . Five national surveys (Table 1) , 7 reviews and 2 meta-analyses (Table 2) , 17 randomised controlled trials (Table 3) , 5 observational studies and 4 initial trials of remifentanil in labour (Table 4 ) and 2 case reports (Table 5) were included in this review. We also refer to two articles in the Czech language indexed in SCOPUS, not in pubmed.gov database. One was a Czech national survey of anaesthesiological approaches to obstetric anaesthesia and analgesia. The second was a description of analgesia for labour approaches and experiences in Great Britain [20] [21] . In the final meta-analysis, two RCTs did not meet the inclusion criteria (measured VAS at 60 min) and were excluded from the meta-analysis (Balki et al., Balcioglu et al.) (ref. [24] [25] ). The remaining 15 RCTs were analyzed.
Characteristics of included trials
A basic description of included RCTs (mode of administration, dosage, lock out interval, number of conversions to epidural analgesia and compared method of analgesia) is sumarized in Table 3 .
Primary endpoint
The combined data from the meta-analysis shown in Table 6 , revealed a statistically significant decrease in the VAS in the remifentanil group ( 27 Douma et al. 33 Douma et al. 43 El-Kerdawy et al. 42 Evron et al. 28 Evron et al. 35 Ismail et al. 44 Ng et al. 40 Stocki et al. 17 Štour et al. 15 Thurlow et al. 46 Tveit et al. 34 Volikas et al. 26 Volmanen et al. 37 Volmanen et al. 41 References Difference in means and 95% CI Comparison of IV opioid analgesia, Entonox, neuraxial analgesia on neonatal outcome Egan 13 Pharmacokinetics and pharmacodynamics of remifentanil Leong et al. 38 A comparison between remifentanil and meperidine for labor analgesia Hill et al. 55 The use of remifentanil in obstetric anaesthesia and analgesia Hinova et al. 56 Effi cacy of remifentanil as a labor analgesic Volmanen et al. 57 Comparison of paracervical block, pudendal block, IV remifentanil and nitrous oxide Kranke et al. 
DISCUSSION AND REVIEW OF THE LITERATURE
To the best of our knowledge, this is the first metaanalysis of RCTs on the efficacy of remifentanil during labour, regardless of study design, mode of application and dosage of remifentanil during labour.
The strength of the meta-analysis is inclusion of all RCTs published until the end of 2014 with the exception of RCTs which failed to meet the criteria for analysis.
The key information is that 12 RCTs showed a statistically significant decrease in VAS in the first hour. Two showed nonsignificant change in VAS in the first hour (Volikas et al., Blair et al.) and only one (Evron et al.) reported a statistically significant increase in VAS (ref. [26] [27] [28] . The primary outcome of Evron's study was the effect of remifentanil on body temperature during labour 28 . The three studies above confirmed the superiority of remifentanil in terms of analgesic efficacy compared to remifentanil with pethidine during labour.
Safety and efficacy of remifentanil in labour
As published, remifentanil relieves pain in labour during the first stage 15, [29] [30] [31] . Typically described is initial decrease in the intensity of labour pain during the first hour following remifentanil and then a return of pain intensity to initial values , even using a different application method and dose 14, 15, 29, 31, 32 . Despite this course, surprisingly few subsequent applications of epidural analgesia are described for inadequate pain relief using remifentanil (0-10%) which is hard to explain from the published data 28, 29, [33] [34] [35] . During the second stage of labour, pain intensity remains high but the reduction in pain is perceived by the patient as adequate (Table 4 ) (ref. 30, 34 ).
Comparison of the efficacy and safety of remifentanil with other types of analgesia in labour
There are no published RCT studies directly comparing the analgesic efficacy of remifentanil for labour with placebo.
Nitrous oxide
Nitrous oxide in the form of Entonox ® (50% N 2 O a 50% O 2 , LINDE GAS) celebrates a return to the delivery room. Currently available is one Iranian study on the ef- . The analgesic efficacy of remifentanil compared to 50% N 2 O was five times higher than that published by Volmanen et al. 37 Mothers themselves preferred the administration of remifentanil. The disadvantage of remifentanil was a higher level of sedation but no serious episodes of hypoxia (SpO2 <90%) occurred. The authors found no differences in maternal hemodynamics or early postnatal adaptation of newborns.
Pethidine
A systematic review comparing the use of remifentanil and pethidine in the management of labour pain, clearly documents the greater efficacy of remifentanil 38 . In this study, remifentanil was more effective on the VAS scale 25 millimeters, than pethidine within the first hour after application. The maternal satisfaction with remifentanil was higher and necessity for subsequent application of epidural analgesia for inadequate pain relief was lower 39 . Due to the large heterogeneity of dosing schedules of both drugs, it is difficult to draw clear conclusions about the side-effects. There were no differences in the incidence of decreased saturation below 95% or in maternal sedation. Some studies found no difference in cardiotocograph interpretation 33, 40 . On the other hand, one study showed a lower incidence of non-physiological cardiotocograph when remifentanil was administered 35 . All studies confirmed better postpartum neonatal outcome after remifentanil than pethidine (Table 3 ) (ref. 26, 27 ).
Epidural analgesia
The most interesting and most useful in practice, is comparison of remifentanil with epidural analgesia. Although epidural analgesia is provided in less than 15% of labours in some countries, it is the major analgesic method used by anaesthesiologists in obstetrics in the Czech Republic 21 . Currently, few probably doubt that remifentanil administered in the PCA is a less effective analgesic than epidural analgesia 14, 15 . Despite these findings, most studies found no difference in maternal satisfaction with applied method of analgesia 15, 18, 34, [41] [42] [43] [44] . This would suggest that remifentanil provides a weaker but highly acceptable analgesia for the parturient. The explanation for this may be opioid-induced euphoria 41 . In contrast, remifentanil is associated with a higher risk of nausea and vomiting, decreased oxygen saturation under 95% and dose dependent level of sedation 34, 39, 41 . There was no difference in either cardiotocograph interpretation or neonatal outcome between epidural analgesia and remifentanil 15, 28, 34, 41, 43, 44 . No effect on higher incidence of instrumental deliveries, Caesarean Sections or length of (Table 3) (ref. 15, 17 ).
Dosing and mode of remifentanil administration during labour
Remifentanil is administered intravenously using infusion pump with PCA mode preferably without any further IV fluid administered into identical intravenous cannula. Currently available are various products containing remifentanil: Ultiva (GSK, Great Britain), Remifentanil B.Braun (B.Braun, Germany), Remifentanil Kabi (Fresenius Kabi, Germany) and others. The package contains 1 or 2 mg of active substance in the vial. Remifentanil usually needs to be diluted with saline to achieve a concentration of 20 or 50 μg/mL (ref. 15, 20 ). The setup for PCA mode in published studies is variable and optimal dosing schedules have not yet been described (Table 3) (ref. 14 ).
Bolus versus continuus application
The first dose determining studies identified the effective dose as 0.25 -0.5 μg/kg for obstetric analgesia (Table 4 ) (ref. 30, 31 ). Subsequent studies have worked with different dosages ranging from 0.1-0.9 μg/kg in case of conversion of the dose per body weight or fixed bolus 20-50 μg (ref. 15 ). Lock out interval (interval in which the pump does not respond to parturient requirements) varied between 1 and 3 min with the exception of two studies, where the lock out interval was 4.5 min and 5 min 40, 42 . A maximum average single dose of 0.7 μg/kg was published by Tveit. This author also warned about exceeding this dose because of higher risk of desaturation and maternal sedation 34 . On the other hand, D'Onofrio did not apply bolus doses, only continual infusion of remifentanil in a range of 0.025 to 0.15 μg/kg/min (ref. 22 ).
Fixed versus variable dose of remifentanil
Labour pain is intermittent, dynamic and specific with increasing frequency and intensity during labour progression. For this reason, proper timing, dosing and length of lock out interval are important for analgesic efficacy. The beginning of subsequent contractions is also unpredictable due to interindividual variability even with the involvement of highly advanced machine learning methods 45 . This fact could explain the considerable variation in dose and cumulative dose of remifentanil during labour in most published studies 12 . A fixed dose without the option of reacting to actual need can therefore lead to either underdosing with unsufficient pain relief or overdosing associated with side-effects 27, 46 . Some studies refute this concern 33, 40, 43 . The question of preferences of fixed dose or variable dose therefore remains open. Table 5 . Case reports of patients using patient controlled analgesia.
Reference
Case description
Bonner et al. 53 Respiratory arrest in patient using remifentanil in PCA Marr et al. 54 Cardiorespiratory arrest during induced labour while using a remifentanil PCA in patient diagnosed with an intrauterine death at 31 weeks' gestation PCA -Patient controlled analgesia Table 6 . Meta-analysis of study results comparing VAS between t=0 and t=1 hour for remifentanil.
Study
Diff erence in VAS between t=0 and t=1 for Remifentanil (95% CI) P 
Basal infusion
Another controversial issue in the administration of remifentanil at delivery, is application of basal infusion in the period between bolus applications. In studies where basal infusion was used, the dose varied between 0.025 and 0.15 μg/kg/min. Blair et al. reported that basal infusion does not lead to greater analgesic efficacy but only to higher incidence of respiratory depression and maternal sedation 30 . On the other hand, Balki explained the low rate of need for loading epidural analgesia due to inefficacy of remifentanil with administering the variable basal infusion (0.025-0.1 μg/kg/min with bolus dose 0.25 μg/ kg) (ref. 24 ).
Comparison of different modes of administration of remifentanil
Few studies are available that directly compare different modes of administering remifentanil at delivery. Balcioglu et al. compared two PCA modes with different basal infusion of remifentanil. A basal infusion of 0.15 μg/ kg/min was found to be the more effective analgesic dose than 0.1 μg/kg/min without the described difference in adverse effects for both mother and newborn 25 . Balki et al. compared two modes of remifentanil administration, one with variable bolus dose and fixed basal infusion and in contrast, the second with variable basal infusion and fixed bolus dose 24 . Analgesic efficacy, maternal satisfaction and cumulative intake of remifentanil were comparable. Sideeffects, especially drowsiness, were higher in the group with the variable bolus. Apropos the pharmacokinetics of remifentanil and the character of labour pain, initiation of remifentanil administration with the beginning of contraction may not lead to the greatest effect at the time of the most intensive labour pain 47, 48 . For this reason, Volmanen et al. investigated remifentanil administration either at the beginning of contraction or between two contractions 49 . They reported no differences in analgesic efficacy or incidence of side-effects between groups. However, more detailed analysis showed that in a group of patients with long and regular contractions, a bolus dose between contractions can have greater analgesic effects.
Adverse effects of remifentanil in labour
Remifentanil, as with other opioids, can potentially cause serious adverse effects. Various depth of maternal sedation is common 15, 29, 31, 37, 41 . The incidence of sedation in some studies is almost 100% (ref. 24, 31, 34 ). Other frequent negative effects of opioids, including remifentanil are nausea and vomiting. Some publications do not describe a higher incidence in the case of remifentanil 14, 15, 17, 24, 31, 34 . The occurrence of dizziness may disable further use of remifentanil due to risk of falling during verticalization 40, 41 . An incidence of maternal desaturation under 95% is published in 24 -74% of cases 17, 30, 31, 33, 41, 46 . This is no higher than pethidine 38 . Interestingly, desaturation occurs in 40% of parturients inhaling Entonox ® and in 46% of parturients without any analgesia 50, 51 . Episodes of desaturation associated with remifentanil are usually short and rapidly respond to maternal stimulation or oxygen application. The most severe cases may result in apnea and several have been reported 17, [52] [53] [54] . The one requiring artificial ventilation reported by Bonner and McClymont was related to a combination of other factors such as dehydration, exhaustion and vertical position of the parturient 53 . Recently, a case report of cardiac arrest following respiratory arrest after remifentanil was published 54 . Long term opioids (codein, diamorphine) preceded this event in the reported case. Although the full recovery of parturient occurred after resuscitation, fatal intrauterine death took place during the complication. This incident led to recommendations for careful maternal monitoring after remifentanil, including continuous monitoring of respiratory rate and oxygen saturation and one midwife per parturient. There is also the need for rapid availability of anaesthesiologist to deal with any complications 24, 27, [55] [56] [57] . Implementation all of these conditions may not be easy to achieve in an exposed delivery room in a large perinatological center. After the initial labelling of remifentanil as "The poor man's epidural", it seems that for its safe use we must require at least the same conditions as for epidural analgesia 58 .
Adverse effects of remifentanil on the fetus and neonate
Although remifentanil rapidly crosses the placenta into the fetal circulation (88% concentration in the fetus), it is rapidly metabolized and redistributed in newborn (the concentration ratio uterine vein to uterine artery is 0.29) (ref. 16 ). The risk for neonate appears to be minimal. Further studies confirm this and to date no adverse neonatal outcome (Apgar score, uterine blood gases or need to give naloxone) has been proven 14, 15, 17, 22, 23, 30, 43 . Neither has any typical pathological cardiotocograph curve associated with remifentanil in labour been found. One caveat is the small number of cases of impaired neonatal outcome that may cause a feeling of false security around remifentanil use for newborns 29 . For this reason, the necessary equipment of the delivery room for eventual resuscitation of newborns must include naloxone. Based on the current published data, we cannot answer questions concerning the relationship of possible impairment in neonatal outcome and dosage to the method of application of remifentanil.
However, we recommend the following dose regimen without background infusion, low initial dose with the option of bolus adjustment or/and lock out intervals based on clinical status of the parturient and termination of boluses at the start of the second stage of labour, to minimise maternal hypoventilation and adverse postnatal effects on the newborn 59 .
CONCLUSION
This meta-analysis confirms the efficacy of remifentanil for labour. The systematic review describes possible modes of application, dosage and side-effects for mother, fetus/ newborn. However, questions remain which can only be answered by further randomized trials. 
